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Gaseous nitric oxide (NO) is bactericidal in vitro. However whether and how it can be used for the treatment of bacterial lung infections in
patients with cystic ﬁbrosis is unclear. Here we assessed the bactericidal effect of intermittently inhaled 160 ppm NO for 30 min every 4 h in a
Pseudomonas aeruginosa pneumonia model in rats. NO signiﬁcantly reduced P. aeruginosa colony count in rat lungs but did not affect neutrophil
myeloperoxidase function methemoglobin percentage nor plasma nitrite/nitrate levels. This regimen warrants exploration in infected patients with
cystic ﬁbrosis.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Nitric oxide; Inhalation; P. aeruginosa pneumonia; Myeloperoxidase1. Introduction
Cystic fibrosis (CF) is linked to mutations in the epithelial
chloride channel, named CF transmembrane conductance regu-
lator (CFTR) and thus have difficulty mobilizing pulmonary
secretions. Consequently, microbial infections still represent the
most serious clinical complication in CF patients [1]. Antibiotic
treatment, has considerably improved the quality of life and
mortality in individuals with CF, especially for those patients with
infections caused by Pseudomonas aeruginosa, the dominant
infecting organism in the majority of adult CF patients [2].
However, P. aeruginosa as with other microbial pathogens, tend⁎ Corresponding author at: Department of Medicine, Division of Infectious
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http://dx.doi.org/10.1016/j.jcf.2013.01.008lishedto develop resistance to various antibiotics in CF patients. This is
exacerbated when the pathogens in chronic infective states cannot
be eradicated and patients are treated with repeated aggressive
therapeutic courses [2,3]. Thus, alternative antimicrobial treat-
ment strategies need to be developed.
Nitric oxide (NO) affects many physiologic processes [4]
and due to its beneficial effect as a selective pulmonary
vasodilator for pulmonary hypertension NO has been studied
as a therapeutic gas at concentrations of 20–40 ppm for the
treatment of acute respiratory distress syndrome (ARDS) [5]
and is already approved in full-term newborns with persistent
pulmonary hypertension [6].
Endogenous NO also contributes to host defenses against a
wide range of bacteria, fungi and viruses upon up-regulation of
neutrophils, macrophages or epithelial cells following infec-
tion and/or stimulation by cytokines [7–11]. The microbicidal
effect of NO is thought to be mediated by interference with
DNA repair mechanisms, binding to heme containing or thiolby Elsevier B.V. All rights reserved.
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Fig. 1. Effect of high-dose intermittent NO inhalation on Pseudomonas
aeruginosa cell numbers in a lung infection model in rats. Solid bars represent
treatment (160 ppm NO for 30 min every 4 h) and open bars represent control
(continuous room air for 12 or 24 h).
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modulating the host immune response [7,9–11]. These data
warrant the exploration of inhaled exogenous NO for the
treatment of respiratory infections in CF patients; however, little
in vivo data for an optimal treatment strategy are available.
Antimicrobial effects of exogenous NO have been demon-
strated in vitro [12–14] and in a rat model of acute P. aeruginosa
pneumonia [15]. In the latter study, NO was administered
continuously at 40 ppm. Based on our in vitro data [14], we
hypothesized that intermittent inhalation of 160 ppm would be
comparably beneficial in vivo. Here we report that intermittent
high dose NO treatment of rats induced with P. aeruginosa
pneumonia resulted in a significant reduction of P. aeruginosa
bacterial load expressed as colony-forming units (CFUs) in the
airways of the rats. This inhaled antimicrobial NO regimen did
not adversely affect lung inflammation nor did it result in toxic
nitrite/nitrate nor methemoglobin blood levels, suggesting that
this treatment regimen may represent a promising therapeutic
approach for patients with bacterial lung infections.
2. Material and methods
Male Sprague–Dawley rats (300–450 g body weight, Charles
River Labs, St. Constant, Quebec, Canada) were anesthetized with
5% halothane in 100% oxygen and challenged intratracheally with
0.2 mL of 1.2×108CFU ofP. aeruginosa (ATCC strain 27853) or
0.2 mL sterile phosphate buffered saline (PBS), pH 7.4, as
previously described [15]. Thereafter, groups of uninfected animals
(n=6) and P. aeruginosa infected animals (n=20) were treated
with room air (FiO2=0.21, NOb0.5 ppm) or 160 ppm NO in
room air for 30 min every 4 h for 12 h or 24 h. Animals in the NO
treatment groups were continuously monitored in a Plexiglas
chamber, flushed at 10 L/min with a gas mixture of NO in
nitrogen (800 ppm, ViaNOx-H, VIASYS Healthcare, Yorba
Linda, CA, USA), medical-grade air (FiO2=0.21, Praxair,
Mississauga, Ontario, Canada) and medical-grade oxygen to
maintain FiO2=0.21 (Praxair, Mississauga, Ontario, Canada)
using high-accuracy flow meters and a custom gas control
manifold (Pulmonox Medical Inc., Tofield, Canada). A fan
driven soda lime (Sodasorb, WR Grace Company, Cambridge,
MA. USA) absorber module attached to the Plexiglas chamber
circulated the gas in the chamber to remove the CO2 produced
by the rats as well as the NO2 product of the reaction of NO
with oxygen. The gas mixture was monitored continuously by
an electrochemical-based NO, NO2 and O2 analyzer (Aero
Nox, Pulmonox Medical Inc., Tofield, Canada).
Half of the animals were euthanized after 12 h and the balance
at 24 h (1 mL/kg of 2.5% sodium thiopental, intravenously).
Heparinized arterial blood was collected for determination of NO
metabolites [16] and methemoglobin percentage (ABL 3, Radi-
ometer, Copenhagen, Denmark). Lungs were removed en bloc, the
right lung weighed and homogenized (Polytron homogenizer,
Brinkmann, Mississauga, Ontario, Canada) in 3 mL of sterile
sucrose (0.32 M) dissolved in HEPES buffer (10 mM, pH 7.4;
Sigma, St. Louis, MO, USA) for assessment of total pulmonary
bacterial load and neutrophil-derived myeloperoxidase (MPO)
activity using routine methods [16]. The study protocol wasapproved by the University of Western Ontario Animal Care and
Use Committee and was carried out under the supervision of a
veterinarian in accord with international principles on the care and
handling of animals in research as mandated by the Canadian
Council on Animal Care. For statistical analysis the two-tailed
Student's t-test employing a significance level of pb0.05 was
used.3. Results and discussion
Lungs from infected animals treated with room air, appeared
grossly edematous with multifocal areas of hemorrhage (not
shown). High counts of P. aeruginosa CFUs were present at 12
and 24 h after bacterial challenge (Fig. 1). Intermittent inhalation
of 160 ppm NO to infected rats was associated with a sig-
nificantly reduced bacterial load at these time points (Fig. 1). Our
findings are consistent with previous data demonstrating a
modest antibacterial efficacy of continuous exposure of 40 ppm
inhaled NO in rats with P. aeruginosa pneumonia [12]. In vitro
data suggest that higher concentrations of NO administration are
directly bactericidal, while low levels of NO administration may
exert antibacterial effects indirectly via stimulation of the host
immune system [13].
Although intermittently inhaled NO at concentrations of
160 ppmmay be effective in treating human respiratory infections,
NO itself may be toxic resulting in increased inflammation or
inducing methemoglobinemia directly or via other NOmetabolites
such as peroxynitrite. We therefore measured pulmonary MPO
activity, a marker of leukocyte infiltration in rat lung homogenates.
MPO activity increased significantly as a consequence of
pneumonia in room air treated rats at 24 h (Fig. 2). The addition
of NO treatments for up to 24 h did not affect these MPO levels
significantly (Fig. 2). In addition, we monitored plasma nitrite/
nitrate levels. These results were consistent with previous reports
[15], demonstrating that plasma nitrite/nitrate levels continuously
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Fig. 2. Myeloperoxidase activity in infected and un-infected rats, treated with
high-dose intermittent NO. The influx of neutrophils into rat lung tissues was
measured in P. aeruginosa infected and uninfected (PBS) rats. Solid bars represent
treatment (160 ppm NO for 30 min every 4 h) and open bars represent control
(continuous room air for 24 h). ns=statistically not significant.
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Interestingly, the nitrite/nitrate level also increased in room air
treated rats with infection. Presumably this was due to increased
endogenous NO upregulation caused by the presence of the
bacterial infection alone (Fig. 3) This has been previously
reported in human patients with pulmonary infections [17].
Importantly, the infected rats treated with NO did not result in
further increases in plasma nitrite/nitrate levels (Fig. 3).
Finally, blood methemoglobin percent levels did not differ
between the 4 rat groups at 24 h and were all less than 1% (not
shown). Methemoglobin is formed in direct relation to the
concentration of NO and the duration of NO inhalation and
rises to 1% following 30 min of breathing 160 ppm NO. Once
formed, methemoglobin is reduced to hemoglobin by methe-
moglobin reductase. Thus, the predicted metabolic half-life of
methemoglobin is approximately 1 h in humans [18], and likely
to be similar in rats. The baseline methemoglobin percent levels
were measured in this study and also 3.5 h after the last0
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Fig. 3. Plasma nitrite/nitrate levels in P. aeruginosa infected rats treated with
high-dose intermittent NO. Nitrite/nitrate (NOx) levels were determined in plasma
samples of P. aeruginosa infected and uninfected (PBS) rats. Solid bars represent
treatment (160 ppm NO for 30 min every 4 h) and open bars represent control
(continuous room air for 24 h). ns=statistically not significant.exposure of the rats to 160 ppm NO. Similar baseline
methemoglobin percent values and other safety parameters
such as lung function and inflammatory markers have been
determined in a recent phase I study of intermittent 160 ppm
NO treatment in 10 healthy human individuals [19]. We have
shown that intermittent high dose NO treatment in rats with a
pulmonary infection appears to be safe and effective. The
intermittent schedule of high dose NO treatment may be very
practical from a clinical perspective due to the freedom of
movement between treatment courses in CF patients with
respiratory infections. Taken together, with the healthy human
and these data provide sufficient rationale to explore this
antimicrobial regimen in humans with pulmonary infections.
However, whether such a treatment regimen is equally effective
in CF patients as in our rat study is not yet known. The data
suggests that further studies in CF patients are warranted.Acknowledgments
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